<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611559</url>
  </required_header>
  <id_info>
    <org_study_id>110478</org_study_id>
    <nct_id>NCT00611559</nct_id>
  </id_info>
  <brief_title>Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children</brief_title>
  <official_title>Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The new formulation administered as a 4th consecutive dose will be compared to the current
      formulation of the vaccine in this partially double blind study.

      The study will be double-blind with respect to the two DTPa-HBV-IPV/Hib groups. The study
      will be open with respect to the DTPa-HBV-IPV group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 14, 2008</start_date>
  <completion_date type="Actual">June 25, 2008</completion_date>
  <primary_completion_date type="Actual">June 25, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose</measure>
    <time_frame>One month after the booster dose</time_frame>
    <description>Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose</measure>
    <time_frame>One month after the booster dose</time_frame>
    <description>Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</measure>
    <time_frame>One month after the booster dose</time_frame>
    <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</measure>
    <time_frame>One month after the booster dose</time_frame>
    <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose</measure>
    <time_frame>One month after the booster dose</time_frame>
    <description>Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL
Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HB Antibodies Concentration</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Concentration of anti-HB antibodies given as GMC in mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL
Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Antibodies Concentration</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Concentration of anti-PRP antibodies given as GMC in µg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose</measure>
    <time_frame>Before the booster dose administration (at baseline)</time_frame>
    <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria and Anti-tetanus Antibodies Concentration</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose</measure>
    <time_frame>Before the booster dose administration (at baseline)</time_frame>
    <description>Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose</measure>
    <time_frame>Before the booster dose</time_frame>
    <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-poliovirus Antibodies Titer</measure>
    <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
    <description>Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms</measure>
    <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>Within the 31-day (Day 0-30) post-vaccination period</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>Up to one month after the booster dose administration</time_frame>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Poliomyelitis</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Infanrix hexa Preservative-Free Formulation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix hexa Preservative-Containing Formulation Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix penta Preservative-Free Formulation Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™ penta</intervention_name>
    <description>Subjects received a booster dose</description>
    <arm_group_label>Infanrix penta Preservative-Free Formulation Group</arm_group_label>
    <other_name>Pediarix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™ hexa</intervention_name>
    <description>Subjects received a booster dose</description>
    <arm_group_label>Infanrix hexa Preservative-Containing Formulation Group</arm_group_label>
    <arm_group_label>Infanrix hexa Preservative-Free Formulation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  Subjects must have completed full three-dose primary vaccination course with
             DTPa-HBV-IPV/Hib or DTPa-HBV-IPV in the primary study DTPa-HBV-IPV-109 (study
             NCT00320463).

          -  A male or female between, and including 18 and 23 months of age at the time of the
             booster vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the booster dose of study vaccine, or planned use during the
             study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the booster dose.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within 30 days of the booster dose.

          -  Participation in another clinical study, between the primary study NCT00320463 and the
             present booster study, or at any time during the study, in which the subject has been
             or will be exposed to an investigational or a non-investigational product.

          -  Previous booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis and
             hepatitis B since the conclusion visit of study NCT00320463.

          -  Previous booster vaccination against Haemophilus influenzae diseases in the
             DTPa-HBV-IPV/Hib groups, since the conclusion visit of study NCT00320463.

          -  History of exposure to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B
             and/or Haemophilus influenzae disease since the conclusion visit of study NCT00320463.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the booster dose or planned administration during the study period.

          -  Any of the following adverse events having occurred after previous administration of
             DTP vaccine:

          -  Hypersensitivity reaction due to the vaccine.

          -  Encephalopathy defined as an acute, severe central nervous system disorder of unknown
             etiology occurring within 7 days following previous vaccination and generally
             consisting of major alterations in consciousness, unresponsiveness, generalized or
             focal seizures that persist more than a few hours, with failure to recover within 24
             hours.

          -  Any of the following adverse events having occurred after previous administration of
             DTP vaccine:

          -  Temperature of &gt;= 40.0 °C (axillary temperature), within 48 hours of vaccination.

          -  Collapse or shock-like state within 48 hours of vaccination.

          -  Persistent, inconsolable crying lasting &gt;= 3 hours, occurring within 48 hours of
             vaccination.

          -  Convulsions with or without fever, occurring within 3 days of vaccination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murmansk</city>
        <zip>183046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perm</city>
        <zip>614022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syktyvkar</city>
        <zip>167000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <results_first_submitted>June 22, 2009</results_first_submitted>
  <results_first_submitted_qc>June 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2009</results_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infanrix hexa</keyword>
  <keyword>combined vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110478</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infanrix Hexa Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="P2">
          <title>Infanrix Hexa Preservative-containing Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="P3">
          <title>Infanrix Penta Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infanrix Hexa Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="B2">
          <title>Infanrix Hexa Preservative-containing Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="B3">
          <title>Infanrix Penta Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="283"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.2" spread="1.61"/>
                    <measurement group_id="B2" value="21.3" spread="1.57"/>
                    <measurement group_id="B3" value="21.2" spread="1.62"/>
                    <measurement group_id="B4" value="21.2" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White - Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose</title>
        <description>Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)</description>
        <time_frame>One month after the booster dose</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose</title>
          <description>Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose</title>
        <description>Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)</description>
        <time_frame>One month after the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose</title>
          <description>Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</title>
        <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)</description>
        <time_frame>One month after the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</title>
          <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</title>
        <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)</description>
        <time_frame>One month after the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose</title>
          <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-poliovirus type 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose</title>
        <description>Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)</description>
        <time_frame>One month after the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose</title>
          <description>Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="49.8" upper_limit="86.3"/>
                    <measurement group_id="O2" value="84.2" lower_limit="61.5" upper_limit="115.4"/>
                    <measurement group_id="O3" value="43.9" lower_limit="22.4" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.6" lower_limit="369.7" upper_limit="614.4"/>
                    <measurement group_id="O2" value="428.3" lower_limit="311.2" upper_limit="589.5"/>
                    <measurement group_id="O3" value="221.1" lower_limit="120.3" upper_limit="406.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.1" lower_limit="303.2" upper_limit="576.6"/>
                    <measurement group_id="O2" value="384.1" lower_limit="271.3" upper_limit="544.0"/>
                    <measurement group_id="O3" value="251.6" lower_limit="143.9" upper_limit="439.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose</title>
        <description>Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL
Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose</title>
          <description>Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL
Number of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 10 mIU/mL Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 100 mIU/mL Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 100 mIU/mL Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HB Antibodies Concentration</title>
        <description>Concentration of anti-HB antibodies given as GMC in mIU/mL</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HB Antibodies Concentration</title>
          <description>Concentration of anti-HB antibodies given as GMC in mIU/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.5" lower_limit="114.3" upper_limit="233.7"/>
                    <measurement group_id="O2" value="161.2" lower_limit="111.5" upper_limit="232.9"/>
                    <measurement group_id="O3" value="196.9" lower_limit="124.2" upper_limit="312.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4668.0" lower_limit="2861.4" upper_limit="7615.3"/>
                    <measurement group_id="O2" value="4962.3" lower_limit="3289.7" upper_limit="7485.4"/>
                    <measurement group_id="O3" value="3867.8" lower_limit="1751.4" upper_limit="8541.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose</title>
        <description>Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL
Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose</title>
          <description>Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL
Number of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 0.15 µg/mL Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0 µg/mL Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1.0 µg/mL Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Antibodies Concentration</title>
        <description>Concentration of anti-PRP antibodies given as GMC in µg/mL</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRP Antibodies Concentration</title>
          <description>Concentration of anti-PRP antibodies given as GMC in µg/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="16.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="34.7" lower_limit="22.9" upper_limit="52.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.2" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose</title>
        <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL</description>
        <time_frame>Before the booster dose administration (at baseline)</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose</title>
          <description>Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-diphtheria and Anti-tetanus Antibodies Concentration</title>
        <description>Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-diphtheria and Anti-tetanus Antibodies Concentration</title>
          <description>Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.1" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-diphtheria Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.9" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.5" upper_limit="4.5"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1.4" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.6" upper_limit="6.7"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.3" upper_limit="9.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="2.8" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose</title>
        <description>Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose</title>
          <description>Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose</title>
        <description>Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL</description>
        <time_frame>Before the booster dose administration (at baseline)</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose</title>
          <description>Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.2" upper_limit="8.4"/>
                    <measurement group_id="O2" value="6.2" lower_limit="5.0" upper_limit="7.8"/>
                    <measurement group_id="O3" value="7.1" lower_limit="5.3" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="18.4" upper_limit="32.6"/>
                    <measurement group_id="O2" value="22.1" lower_limit="16.3" upper_limit="30.0"/>
                    <measurement group_id="O3" value="23.8" lower_limit="17.3" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="13.4" upper_limit="23.0"/>
                    <measurement group_id="O2" value="13.7" lower_limit="10.3" upper_limit="18.1"/>
                    <measurement group_id="O3" value="15.0" lower_limit="10.3" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose</title>
        <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50</description>
        <time_frame>Before the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose</title>
          <description>Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-poliovirus type 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-poliovirus Antibodies Titer</title>
        <description>Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)</description>
        <time_frame>Before (Pre) and one month after (Post) the booster dose</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-poliovirus Antibodies Titer</title>
          <description>Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-poliovirus type 1 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.5" lower_limit="67.9" upper_limit="167.0"/>
                    <measurement group_id="O2" value="120.4" lower_limit="76.9" upper_limit="188.4"/>
                    <measurement group_id="O3" value="85.9" lower_limit="47.1" upper_limit="156.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 1 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1237.1" lower_limit="940.7" upper_limit="1626.9"/>
                    <measurement group_id="O2" value="1939.8" lower_limit="1465.1" upper_limit="2568.2"/>
                    <measurement group_id="O3" value="979.5" lower_limit="539.4" upper_limit="1778.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 2 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.4" lower_limit="96.9" upper_limit="215.2"/>
                    <measurement group_id="O2" value="102.5" lower_limit="68.2" upper_limit="154.2"/>
                    <measurement group_id="O3" value="95.3" lower_limit="56.3" upper_limit="161.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 2 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1412.0" lower_limit="1096.4" upper_limit="1818.5"/>
                    <measurement group_id="O2" value="1900.6" lower_limit="1399.7" upper_limit="2580.7"/>
                    <measurement group_id="O3" value="916.3" lower_limit="498.1" upper_limit="1685.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 3 Pre</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="68.0" upper_limit="143.2"/>
                    <measurement group_id="O2" value="68.9" lower_limit="47.0" upper_limit="101.1"/>
                    <measurement group_id="O3" value="77.5" lower_limit="41.9" upper_limit="143.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-poliovirus type 3 Post</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1485.9" lower_limit="1041.4" upper_limit="2120.3"/>
                    <measurement group_id="O2" value="1828.7" lower_limit="1303.8" upper_limit="2565.1"/>
                    <measurement group_id="O3" value="605.6" lower_limit="264.0" upper_limit="1389.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite</description>
        <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Symptoms</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Within the 31-day (Day 0-30) post-vaccination period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above</description>
        <time_frame>Up to one month after the booster dose administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infanrix Hexa Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O2">
            <title>Infanrix Hexa Preservative-containing Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
          </group>
          <group group_id="O3">
            <title>Infanrix Penta Preservative-free Formulation Group</title>
            <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
          <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infanrix Hexa Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="E2">
          <title>Infanrix Hexa Preservative-containing Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa</description>
        </group>
        <group group_id="E3">
          <title>Infanrix Penta Preservative-free Formulation Group</title>
          <description>Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

